Market Place
Sourcing Support
New CIMZIA Data For Rheumatic Diseases In Pregnancy, High RF RA
13 Jun 2024 //
PR NEWSWIRE
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients
11 Nov 2023 //
PR NEWSWIRE
UCB`s Biologic Cimzia (certolizumab pegol) Receives Approval in the U.S.
08 Nov 2023 //
FDA
UCB`s Biologic Cimzia (Certolizumab Pegol) Receives Approval in the U.S.
22 Dec 2022 //
FDA
Biogen and Xbrane Announce Commercialization and License Agreement for CIMZIA
07 Feb 2022 //
GLOBENEWSWIRE
UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment
30 Oct 2020 //
UCB
CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis
18 Aug 2020 //
CLINICALTRIALSARENA
EMA expands label for UCB`s Cimzia in axial spondyloarthritis
06 Aug 2020 //
PHARMAFILE
CIMZIA[®] is the First and Only Biologic Approved in Europe with the Option
04 Aug 2020 //
PRESS RELEASE
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA®
07 Jul 2020 //
PRNEWSWIRE
Bio-Rad launches anti-certolizumab pegol antibodies
05 May 2020 //
SELECTSCIENCE
UCB`s Cimzia is Making Inroads in the Treatment of Axial Disease
29 Apr 2020 //
PR NEWSWIRE
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab
21 Oct 2019 //
BUSINESSWIRE
UCB continues global development of Cimzia
22 Jul 2019 //
THE PHARMALETTER
NICE final guidance published for Cimzia
18 Apr 2019 //
PHARMA TIMES
FDA label expansion for UCB`s Cimzia
01 Apr 2019 //
PHARMA TIMES
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved
29 Mar 2019 //
PR NEWSWIRE
US FDA approves UCB`s Cimzia to treat patients with a type of infla arthritis
29 Mar 2019 //
PHARMABIZ
NICE nod for Almirall`s Ilumetri, UCB`s Cimzia
11 Mar 2019 //
PHARMA TIMES
UCB brings promising plaque psoriasis data to EADV 2018
18 Sep 2018 //
PHARMA FILE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.